YZYBIO-B (02496): Two M 701 Research Findings Selected for Presentation at 2026 ASCO Annual Meeting

Stock News

Apr 23

Yuzhiyou Biotech-B (02496) has announced that two clinical research findings related to its core innovative bispecific antibody product, M 701, have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Specifically, the Phase III clinical study results of M 701 for treating malignant ascites have been chosen for an oral presentation in the Clinical Science Symposium. Concurrently, the Phase II clinical research results for M 701 in the treatment of malignant pleural effusion have been selected for a poster presentation. This achievement marks another significant milestone for the M 701 project on the international oncology stage, demonstrating its continued recognition and attention from the global academic community in the treatment of malignant serous cavity effusions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1192949223"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192949223\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192949223?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192949223","market":"other","top_or_hot":-1,"title":"YZYBIO-B (02496): Two M 701 Research Findings Selected for Presentation at 2026 ASCO Annual Meeting","media":"Stock News","content":"<p>Yuzhiyou Biotech-B (02496) has announced that two clinical research findings related to its core innovative bispecific antibody product, M 701, have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Specifically, the Phase III clinical study results of M 701 for treating malignant ascites have been chosen for an oral presentation in the Clinical Science Symposium. Concurrently, the Phase II clinical research results for M 701 in the treatment of malignant pleural effusion have been selected for a poster presentation. This achievement marks another significant milestone for the M 701 project on the international oncology stage, demonstrating its continued recognition and attention from the global academic community in the treatment of malignant serous cavity effusions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>YZYBIO-B (02496): Two M 701 Research Findings Selected for Presentation at 2026 ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYZYBIO-B (02496): Two M 701 Research Findings Selected for Presentation at 2026 ASCO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-23 19:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Yuzhiyou Biotech-B (02496) has announced that two clinical research findings related to its core innovative bispecific antibody product, M 701, have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Specifically, the Phase III clinical study results of M 701 for treating malignant ascites have been chosen for an oral presentation in the Clinical Science Symposium. Concurrently, the Phase II clinical research results for M 701 in the treatment of malignant pleural effusion have been selected for a poster presentation. This achievement marks another significant milestone for the M 701 project on the international oncology stage, demonstrating its continued recognition and attention from the global academic community in the treatment of malignant serous cavity effusions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02496","symbol_name":"友芝友生物-B","start_time":0,"source_url":"","article_id":"1192949223","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192949223","pubTimestamp":1776944466,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Yuzhiyou Biotech-B (02496) has announced that two clinical research findings related to its core innovative bispecific antibody product, M 701, have been selected for presentation at the 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02496":"友芝友生物-B","BK1161":"生物科技"},"translate_title":"YZYBIO-B(02496)：两项M 701研究成果入选2026年ASCO年会上展示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02496":1},"content_text":"Yuzhiyou Biotech-B (02496) has announced that two clinical research findings related to its core innovative bispecific antibody product, M 701, have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Specifically, the Phase III clinical study results of M 701 for treating malignant ascites have been chosen for an oral presentation in the Clinical Science Symposium. Concurrently, the Phase II clinical research results for M 701 in the treatment of malignant pleural effusion have been selected for a poster presentation. This achievement marks another significant milestone for the M 701 project on the international oncology stage, demonstrating its continued recognition and attention from the global academic community in the treatment of malignant serous cavity effusions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}